Rhenman & Partners Asset Management AB Grows Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Rhenman & Partners Asset Management AB grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 39.7% in the fourth quarter, Holdings Channel reports. The fund owned 23,750 shares of the company’s stock after acquiring an additional 6,750 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Krystal Biotech were worth $3,721,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. BNP Paribas Financial Markets increased its position in Krystal Biotech by 346.8% in the third quarter. BNP Paribas Financial Markets now owns 10,433 shares of the company’s stock worth $1,899,000 after buying an additional 8,098 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Krystal Biotech by 3.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock worth $840,000 after acquiring an additional 153 shares during the last quarter. Hilltop Holdings Inc. bought a new stake in Krystal Biotech in the 3rd quarter valued at about $209,000. State Street Corp lifted its holdings in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Krystal Biotech by 15.1% during the third quarter. Wellington Management Group LLP now owns 12,680 shares of the company’s stock worth $2,308,000 after purchasing an additional 1,660 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on KRYS. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $220.00.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Down 3.8 %

NASDAQ:KRYS opened at $171.30 on Friday. The stock has a market cap of $4.93 billion, a P/E ratio of 57.29 and a beta of 0.75. The business’s 50-day moving average price is $173.27 and its two-hundred day moving average price is $173.18. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm posted $0.30 earnings per share. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. On average, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).